Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

Phase 2 Unknown 10 enrolled Peking University People's Hospital

NaSingle-groupOpen-labelTreatment

Summary

This study aims to explore the clinical characteristics and mechanism of inhibitors of janus kinase in the treatment of idiopathic inflammatory myopathies

Timeline

Start: 2022-06-10
Primary completion: 2023-03-01
Completion: 2023-06-01

Publications

Xing X, Li Y, Liu Q, Wang N, Zhang K, Mo W, Zhao L, Zhang J, Ma K, Zhao X, Lu D, He J. Tofacitinib treatment for active dermatomyositis and anti-synthetase syndrome: a prospective cohort pilot study. Rheumatology (Oxford). 2025 Jun 1;64(6):3756-3766. doi: 10.1093/rheumatology/keaf046.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Baricitinib	Small molecule	2 mg	Oral
Subject	Baricitinib	Small molecule	4 mg	Oral
Subject	Tofacitinib	Small molecule	5 mg	Oral

Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

Summary

Timeline

Publications

Drugs

Indications